全文获取类型
收费全文 | 74篇 |
免费 | 0篇 |
专业分类
化学工业 | 5篇 |
金属工艺 | 1篇 |
轻工业 | 3篇 |
无线电 | 4篇 |
一般工业技术 | 7篇 |
冶金工业 | 49篇 |
自动化技术 | 5篇 |
出版年
2021年 | 2篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2014年 | 1篇 |
2013年 | 1篇 |
2012年 | 3篇 |
2011年 | 1篇 |
2010年 | 1篇 |
2009年 | 4篇 |
2008年 | 1篇 |
2007年 | 2篇 |
2005年 | 1篇 |
2002年 | 1篇 |
1999年 | 1篇 |
1998年 | 20篇 |
1997年 | 9篇 |
1996年 | 4篇 |
1994年 | 4篇 |
1987年 | 4篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1970年 | 1篇 |
1964年 | 1篇 |
1959年 | 1篇 |
1918年 | 1篇 |
排序方式: 共有74条查询结果,搜索用时 15 毫秒
1.
WI Bensinger KS Schiffman L Holmberg FR Appelbaum R Maziarz P Montgomery E Ellis S Rivkin P Weiden K Lilleby S Rowley S Petersdorf JP Klarnet W Nichols A Hertler R McCroskey CH Weaver CD Buckner 《Canadian Metallurgical Quarterly》1997,19(12):1183-1189
The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n = 32) or responsive (n = 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n = 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median of 423 days (range 353-934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (n = 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens. 相似文献
2.
E Galanis J Buckner D Kimmel R Jenkins B Alderete J O''Fallon CH Wang BW Scheithauer CD James 《Canadian Metallurgical Quarterly》1998,13(4):717-724
ND10 are recently characterized nuclear domains that are composed of 0.5 microm sized, precisely circumscribed dots in cultured human cell lines. To investigate the distribution and number of ND10 on various types of normal and neoplastic human tissues, we carried out immunostaining and immunoprecipitation analyses with monoclonal antibodies 138 and 1150. The number of ND10 varied from 1 to 10 or more in various tissues as did their size. ND10 were diffusely located in early embryonic and normal tissues, except for the exocrine and endocrine cells of the pancreas and for hepatocytes. In normal squamous mucosa, basal cells had more ND10 than did differentiated superficial squamous cells. The number and size of ND10 were markedly increased in malignant neoplasms but were similar in benign tumors and corresponding normal tissues. Sex hormone-related normal tissues, such as the endometrium or myometrium, and neoplasms strongly stained for ND10. The distribution pattern of ND10 in human tissues indicates that they are conserved nuclear substructures that are closely associated with cellular differentiation, hormonal stimulation, and oncogenesis. 相似文献
3.
CH Weaver LS Schwartzberg R Birch FA Greco S Rhinehart J Hainsworth T Beeker H Price L Geier J Foster J West B Hazelton CD Buckner 《Canadian Metallurgical Quarterly》1997,37(9):896-903
BACKGROUND: There is great interpatient variability in the number of peripheral blood stem cells collected, as measured by CD34+ cell content, after the administration of chemotherapy and a growth factor. The ability to predict patients who fail to yield adequate quantities of CD34+ cells would be of value. However, very few reports include large numbers of patients treated in an identical fashion. STUDY DESIGN AND METHODS: Between 1991 and 1995, 497 consecutive patients with a variety of malignant diseases received cyclophosphamide (4 g/m2), etoposide (600 mg/m2), and granulocyte-colony-stimulating factor (6 micrograms/kg/day) for mobilization and collection of a target dose > or = 2.5 x 10(8) CD34+ cells per kg. Multivariate analyses were performed to determine the factors associated with failure to achieve this target harvest. RESULTS: A median of 14.71 x 10(6) CD34+ cells per kg (range, 0.08-137.55) was harvested with a median of 2 (range, 1-11) apheresis procedures. Ninety-one percent of patients yielded > or = 2.5 x 10(5) CD34+ cells per kg. Patients with Stage II-III breast cancer, who had pretreatment platelet counts > or = 150 x 10(9) per L and patients who underwent < or = 1 prior chemotherapy regimen had improved CD34+ cell yields. However, most patients with adverse risk factors yielded > or = 2.5 x 10(6) CD34+ cells per kg. CONCLUSION: A regimen of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor led to the successful collection of adequate numbers of CD34+ cells in most patients without excessive toxicity. These observations confirm previous reports that intense prior therapy adversely affects the quantity of CD34+ cells harvested. Pretreatment and posttreatment variables did not predict with any certainty the small fraction of patients who fail to yield > or = 2.5 x 10(6) CD34+ cells per kg via multiple apheresis procedures. 相似文献
4.
Previous research has identified user concerns about biometric authentication technology, but most of this research has been
conducted in European contexts. There is a lack of research that has investigated attitudes towards biometric technology in
other cultures. To address this issue, data from India, South Africa and the United Kingdom were collected and compared. Cross-cultural
attitudinal differences were seen, with Indian respondents viewing biometrics most positively while respondents from the United
Kingdom were the least likely to have a positive opinion about biometrics. Multiple barriers to the acceptance of biometric
technology were identified with data security and health and safety fears having the greatest overall impact on respondents’
attitudes towards biometrics. The results of this investigation are discussed with reference to Hofstede’s cultural dimensions
and theories of technology acceptance. It is argued that contextual issues specific to each country provide a better explanation
of the results than existing theories based on Hofstede’s model. We conclude that cultural differences have an impact on the
way biometric systems will be used and argue that these factors should be taken into account during the design and implementation
of biometric systems. 相似文献
5.
E Galanis JC Buckner BW Scheithauer DW Kimmel PJ Schomberg DG Piepgras 《Canadian Metallurgical Quarterly》1998,82(10):1915-1920
BACKGROUND: Meningeal hemangiopericytoma is an uncommon neoplasm with a high propensity for recurrence. The purpose of this study was to analyze the efficacy of different treatment options in patients with recurrent disease. METHODS: The records of all patients with recurrent meningeal hemangiopericytoma treated at the study institution between 1976 and 1996 were reviewed. RESULTS: Thirty-four consecutive patients were studied. The mainstay of treatment was brain surgery in 21 patients (62%); the median time to recurrence from surgery was 12 months. Ten patients (29%) had 20 recurrent central nervous system (CNS) lesions treated by stereotactic radiosurgery. Of these, 3 previously nonirradiated patients (all with lesion size < 25 mm) achieved a complete response, which persisted at a median of 3 years. In 14 lesions (70%) a partial response (PR) occurred with a median duration of 12 months, whereas 3 lesions (15%) remained stable. Two patients with inoperable CNS lesions received external beam radiation therapy and both had PRs lasting 14 and 24 months, respectively. Nine patients (26%) received radiation therapy for metastatic disease. Of these, seven patients remained stable with good symptomatic relief, and two patients experienced tumor progression. Chemotherapy with doxorubicin-containing regimens was administered in 7 patients (21%); there was only 1 PR that lasted 8 months. The median survival from first recurrence was 4.6 years. CONCLUSIONS: Surgical management is important for the successful treatment of patients with recurrent meningeal hemangiopericytoma. Radiosurgery plays a definite role in the treatment of smaller recurrent CNS lesions. Radiation therapy is helpful in the management of inoperable tumors. More effective chemotherapeutic agents are needed. 相似文献
6.
Building memories: remembering and forgetting of verbal experiences as predicted by brain activity 总被引:3,自引:0,他引:3
AD Wagner DL Schacter M Rotte W Koutstaal A Maril AM Dale BR Rosen RL Buckner 《Canadian Metallurgical Quarterly》1998,281(5380):1188-1191
A fundamental question about human memory is why some experiences are remembered whereas others are forgotten. Brain activation during word encoding was measured using blocked and event-related functional magnetic resonance imaging to examine how neural activation differs for subsequently remembered and subsequently forgotten experiences. Results revealed that the ability to later remember a verbal experience is predicted by the magnitude of activation in left prefrontal and temporal cortices during that experience. These findings provide direct evidence that left prefrontal and temporal regions jointly promote memory formation for verbalizable events. 相似文献
7.
8.
Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma
JC Buckner PA Burch TL Cascino JR O''Fallon BW Scheithauer 《Canadian Metallurgical Quarterly》1998,36(1):65-70
The aim of this study was to investigate the influence of interferon-alpha (IFN-alpha) on bone marrow fibrosis associated with chronic myelogenous leukemia (CML). Eighty-two bone marrow biopsies from 41 patients in chronic phase CML were stained with Snook's reticulin stain for argyrophilic fibers. Grading of reticulin fibrosis (scale of 1 to 4) was according to the quantity and pattern of distribution of reticulin. The interval between biopsies was a median of 25 months (range 12 to 40 months). Patients had been treated with IFN-alpha for at least 12 months, were still on IFN-alpha therapy during the study, and had achieved at least a complete hematological response. Before the start of IFN-alpha therapy, reticulin fibrosis was grade 1-2 in 23 patients (56%) and grade 3-4 in 18 (44%). During IFN-alpha therapy, reticulin fibrosis in bone marrow did not worsen or was reduced in 33 patients (80%) and increased by one grade in eight patients (20%). Only five patients (12%) with limited fibrosis (grade 1-2) before start of IFN-alpha therapy showed an increase towards significant fibrosis (grade 3-4), while eight of the 18 patients (44%) with grade 3-4 fibrosis achieved a decrease of fiber content in bone marrow. In summary, IFN-alpha was not associated with an enhancing effect on myelofibrosis in patients with CML and may have prevented increasing fibrosis in patients who respond to therapy. 相似文献
9.
10.
"The hypothesis tested was that high agreement among the ratings assigned the same men by different raters does not necessarily imply predictable ratings." 3 superior officers rated 100 submariners on personal adjustment and technical competence. Each rating group was divided into 4 samples for interrater agreement. Correlations were computed with 3 predictor variables. The results support the hypothesis given. (PsycINFO Database Record (c) 2010 APA, all rights reserved) 相似文献